Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).
Vaduganathan M, Greene SJ, Ambrosy AP, Mentz RJ, Fonarow GC, Zannad F, Maggioni AP, Konstam MA, Subacius HP, Nodari S, Butler J, Gheorghiade M; EVEREST Trial Investigators. Vaduganathan M, et al. Among authors: subacius hp. Am J Cardiol. 2013 Dec 1;112(11):1763-9. doi: 10.1016/j.amjcard.2013.07.020. Epub 2013 Oct 4. Am J Cardiol. 2013. PMID: 24095030 Free PMC article.
Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Vaduganathan M, Ambrosy AP, Greene SJ, Mentz RJ, Subacius HP, Maggioni AP, Swedberg K, Nodari S, Zannad F, Konstam MA, Butler J, Gheorghiade M; EVEREST trial investigators. Vaduganathan M, et al. Among authors: subacius hp. Circ Heart Fail. 2012 Nov;5(6):750-8. doi: 10.1161/CIRCHEARTFAILURE.112.970525. Epub 2012 Oct 9. Circ Heart Fail. 2012. PMID: 23051949 Clinical Trial.
Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial.
Sarma S, Mentz RJ, Kwasny MJ, Fought AJ, Huffman M, Subacius H, Nodari S, Konstam M, Swedberg K, Maggioni AP, Zannad F, Bonow RO, Gheorghiade M; EVEREST investigators. Sarma S, et al. Eur J Heart Fail. 2013 Feb;15(2):194-202. doi: 10.1093/eurjhf/hfs153. Epub 2012 Oct 11. Eur J Heart Fail. 2013. PMID: 23059198 Free PMC article. Clinical Trial.
Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
Greene SJ, Vaduganathan M, Lupi L, Ambrosy AP, Mentz RJ, Konstam MA, Nodari S, Subacius HP, Fonarow GC, Bonow RO, Gheorghiade M; EVEREST Trial Investigators. Greene SJ, et al. Among authors: subacius hp. Am J Cardiol. 2013 Feb 15;111(4):574-81. doi: 10.1016/j.amjcard.2012.10.042. Epub 2012 Dec 1. Am J Cardiol. 2013. PMID: 23206923 Clinical Trial.
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial.
Butler J, Subacius H, Vaduganathan M, Fonarow GC, Ambrosy AP, Konstam MA, Maggioni A, Mentz RJ, Swedberg K, Zannad F, Gheorghiade M; EVEREST Investigators. Butler J, et al. J Am Coll Cardiol. 2013 Feb 5;61(5):571-9. doi: 10.1016/j.jacc.2012.10.025. Epub 2012 Dec 12. J Am Coll Cardiol. 2013. PMID: 23246389 Free article. Clinical Trial.
Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
Ambrosy AP, Vaduganathan M, Mentz RJ, Greene SJ, Subačius H, Konstam MA, Maggioni AP, Swedberg K, Gheorghiade M. Ambrosy AP, et al. Am Heart J. 2013 Feb;165(2):216-25. doi: 10.1016/j.ahj.2012.11.004. Epub 2012 Dec 29. Am Heart J. 2013. PMID: 23351825 Clinical Trial.
Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial.
Girerd N, Pang PS, Swedberg K, Fought A, Kwasny MJ, Subacius H, Konstam MA, Maggioni A, Gheorghiade M, Zannad F; EVEREST investigators. Girerd N, et al. Eur J Heart Fail. 2013 Nov;15(11):1228-35. doi: 10.1093/eurjhf/hft100. Epub 2013 Jun 19. Eur J Heart Fail. 2013. PMID: 23787720 Free article.
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Greene SJ, Gheorghiade M, Vaduganathan M, Ambrosy AP, Mentz RJ, Subacius H, Maggioni AP, Nodari S, Konstam MA, Butler J, Filippatos G; EVEREST Trial investigators. Greene SJ, et al. Eur J Heart Fail. 2013 Dec;15(12):1401-11. doi: 10.1093/eurjhf/hft110. Epub 2013 Jul 11. Eur J Heart Fail. 2013. PMID: 23845795 Free PMC article. Clinical Trial.
The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.
Greene SJ, Vaduganathan M, Wilcox JE, Harinstein ME, Maggioni AP, Subacius H, Zannad F, Konstam MA, Chioncel O, Yancy CW, Swedberg K, Butler J, Bonow RO, Gheorghiade M; EVEREST Trial Investigators. Greene SJ, et al. JACC Heart Fail. 2013 Dec;1(6):488-96. doi: 10.1016/j.jchf.2013.08.005. Epub 2013 Dec 2. JACC Heart Fail. 2013. PMID: 24622000 Free article. Clinical Trial.
58 results